AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 ...
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback